McDermott has advised Acticor Biotech, a clinical stage biopharmaceutical company dedicated to developing a drug for the treatment of cardiovascular emergencies, on its initial public offering and the first trading of its shares on Euronext Growth Paris, which took place on November 1, 2021.
Acticor Biotech is developing an innovative drug, glenzocimab, for the treatment of the acute phase of ischemic stroke and other cardiovascular emergencies.
Following the open price offer and the global placement, Acticor Biotech realized a capital increase of EUR 15.5 million.
Acticor Biotech’s IPO is chiefly intended to provide the company with financial means to continue its research and development operations in the context of the final objective of marketing its drug candidate, glenzocimab.
The McDermott team that advised Acticor Biotech comprised:
- David Revcolevschi, partner, Louis Feuillée, Théa Delhaye and Mélanie Chailloleau, associates, on corporate aspects;
- Emmanuelle Trombe, partner, and Caroline Noyrez, associate, on Life Sciences aspects;
- Côme de Saint-Vincent, Counsel, on tax aspects.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.